Top 50 Medical Startup Investors in Denmark

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

PreSeed Ventures is the biggest and most succesful early stage investor in Denmark. For more than 20 years, PreSeed Ventures have assisted and financed talented entrepreneurs with early-stage investments, and we hold more than 70 companies in our portfolio.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

We are an early stage investor investing in Seed and Series A startups.

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Penny Schiffer - CEO & Co-founder @ Raized.ai

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.

Jørleif Joensen

Sound Bioventures is a venture capital fund investing in clinical stage companies.

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Morten Strunge is the current Co-Founder of Nexta.io. He previously worked at Storytel AB as a Board Member.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

DigitalDx Ventures is a Silicon Valley Venture firm uniquely positioned to find, support, mentor and grow the outliers in digital healthcare. DDX invests in early stage companies who effectively and efficiently harness the power of artificial intelligence and big data to profoundly impact outcomes in both diagnostics and therapeutics.

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.

Supporting purpose-driven founders solving systemic challenges to planetary health.

Impacting the future of medicine.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

Amino Collective is an investment firm. They enable entrepreneurs and scientists to establish businesses that generate a better future for all species on Earth. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.

Supporting purpose-driven founders solving systemic challenges to planetary health.

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fund’s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.

Dansk Erhvervsinvestering is a company that assists individuals with investing.

Welcome to Innovestor! We are a Finnish investment company focusing on venture capital, corporate venturing services, and real estate.

p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.

VC for the most ambitious founders in CEE

BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.

Noble Group is a global supply chain manager of energy, power & gas products, metals and carbon steel materials, with interests in key facilities that add value at various stages of its supply chains. Noble Group manages a diversified portfolio of essential natural resources, with integrated sourcing, marketing, processing, financing andtransportation operations. Noble Group's Energy segment encompasses a portfolio of oil liquids and coal products and continues to be a significant driver for the Group’s growth. Gas & Power segment includes their retail energy business Noble Americas Energy Solutions and Gas & Power wholesale operations. In Metals & Mining, Noble Group is one of the world’s leading suppliers with interests in iron ore, aluminium, special ores and alloys across key global locations. The Corporate segment incorporates the Logistics business as well as investments in their major associates. Noble Group (SGX: N21) manages a portfolio of global supply chains covering a range of industrial and energy products. Operating from over 60 locations, Noble facilitates the marketing, processing, financing and transportation of essential raw materials. Sourcing bulk commodities from low cost regions such as South America, South Africa, Australia and Indonesia, the Group supplies high growth demand markets, particularly in Asia and the Middle East. Noble Group is ranked number 77 in the 2015 Fortune Global 500. Noble moves essential resources from producers to consumer across the world. Noble Group's success relies on a rigorously managed balance sheet, effective partnerships and a deep understanding of customer needs. Noble’s core strategy is to be the best company in the world at moving the physical commodity from the producer to the consumer and managing the market, credit and operational risk associated with that. Noble Group's solid financial position comes from a rigorously managed balance sheet with exceptional liquidity and a carefully guided exposure to risk - underpinned by deep relationships with global capital providers. At Noble, they have forged some of the most productive and enterprising partnerships in the industry and they have always believed that as their partners grow, so do they. Noble Group put energy and focus into staying relevant and being valuable to their customers, keeping their interests firmly integrated into their DNA.

Roland Berger is a Founder of Roland Berger, Munich and has been the Roland Berger GmbH's Honorary Chairman since 2010. Today, Roland Berger has grown to become one of the world's top five strategy consulting firms with 50 offices in 36 countries. The company has a workforce of 2,400 and advises leading international industrial andservice enterprises, as well as public institutions. From the company's foundation in 1967 until 2003, Roland was Chief Executive Officer of the firm, and until 2010 Chairman of the Supervisory Board. Prior to founding his strategy consultancy, Roland was employed as a consultant and ultimately partner at a leading American consulting firm based in Milan and Boston. Roland has been appointed to various expert commissions by several German state governments and the federal government. From 2007 to its dissolution in 2014, Roland was a Member of the High Level Group on Administrative Burdens under the leadership of former Bavarian State Premier Dr. Edmund Stoiber, appointed by the European Commission. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations, including Fresenius SE & Co. KGaA (Chairman of the Audit Committee), Bad Homburg; Prime Office REIT-AG, Munich (Chairman of the Supervisory Board); RCS Mediagroup S.p.A.(Vice-President), Milan, Italy. Roland also serves on several international advisory boards, including those of Deutsche Bank AG in Frankfurt, MillerBuckfire in New York and The Blackstone Group in New York. Since 1996 Roland has been a Lecturer and Visiting Professor and since 2000 Honorary Professor for Business Administration and Management Consulting at the Brandenburg Technical University in Cottbus. Furthermore, Roland was appointed a member of the Oxford Martin Commission for Future Generations in 2012. Since 2002, Roland has been on the Business Advisory Council of the State Premier of Saxony-Anhalt and was appointed to the Globalization Council Portugal by the Portuguese President Aníbal Cavaco Silva. Previously, German President Roman Herzog had appointed Roland to the President's Advisory Council for Innovation. Roland has also actively participated in over 20 federal government commissions under Helmut Kohl and Gerhard Schröder. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations and invests in many private and listed companies as well as startups. Roland was Honorary Consul General of the Republic of Finland in Bavaria and Thuringia from 1996 to 2015. Roland is Chairman of the Board of Trustees of the Roland Berger Foundation, which he set up personally with an endowment of EUR 50 million. The Roland Berger Foundation is dedicated to the global protection of human dignity and human rights. Each year it confers the Roland Berger Award for Human Dignity. The Foundation also helps gifted children and young people from underprivileged families across Germany and Italy to gain access to the best possible primary and secondary education. Outside work, Roland pursues his interest in modern art and owns a large collection of artworks, mainly by contemporary artists from Europe, the US, South America and China. Roland also loves classical music and supports the Mahler Chamber Orchestra and Bavarian State Opera, among others. Roland loves hiking and cross-country skiing, especially in the Swiss region of Engadin. Roland studied business administration in Munich and Hamburg. (MBA from the Ludwig-Maximilians-Universität, Munich).

Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.